Intranasal delivery of MSC-derived small extracellular vesicles alleviates motor dysfunction and neuroinflammation in ALS mice and exhibits favorable systemic safety

Abstract Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no curative therapy. Neuroinflammation, glial overactivation, neuromuscular junction (NMJ) damage and neuronal apoptosis are major pathological features of ALS. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) are neuroprotective and anti-inflammatory and can cross the blood-brain barrier. Here, we investigated the therapeutic efficacy and systemic safety of intranasal MSC-sEVs in ALS mice. Methods sEVs were isolated from mesenchymal stem cells using anion exchange chromatography, and then lyophilized. The bioactivity of lyophilized MSC-sEVs was validated in a LPS-induced BV2 microglial inflammation model. The SOD1 G93A mice were administered by nasal administration, and motor function was assessed by grip strength and rotarod tests. Neuromuscular junction (NMJ) integrity in the gastrocnemius muscle was examined by immunofluorescence. Neuroinflammation and mitochondrial function-related proteins in the spinal cord and cerebral cortex were detected by western blot and immunofluorescence. Public transcriptomic datasets were used to explore the correlation between SYF2 and ALS-related molecular signatures and its regulatory role in mitochondrial gene expression. For safety evaluation, male and female C57BL/6 mice were also treated via intranasal administration, body weight, serum liver and kidney biochemical parameters, and liver and kidney histology were assessed. Results MSC-sEVs significantly ameliorated motor dysfunction in ALS mice, protected NMJ integrity, inhibited microglial and astrocyte overactivation, and reduced neuroinflammation. SYF2 was upregulated in ALS patients and correlated with DNA damage-related pathways, while SYF2 silencing upregulated multiple mitochondrial genes enriched in oxidative phosphorylation, suggesting that SYF2 may modulate mitochondrial gene expression in ALS. Safety verification showed that MSC-sEVs caused no adverse effects on mouse growth or liver and kidney function and even improved liver biochemical parameters, showing favorable biosafety. Conclusions Intranasal MSC-sEVs effectively alleviate neuroinflammation, preserve NMJ integrity and rescue motor impairment in ALS mice, with reliable systemic safety. The preserved bioactivity of lyophilized MSC-sEVs and the involvement of SYF2-mediated mitochondrial regulation support MSC-sEVs as a safe and promising translatable therapeutic candidate for ALS.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11160281/v1
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Intranasal delivery of MSC-derived small extracellular vesicles alleviates motor dysfunction and neuroinflammation in ALS mice and exhibits favorable systemic safety

Qing‐Ling Fu, 王树汉, Zhihui Wang, Dong-Xiao Lou et al.
3 links
Research Square
Amyotrophic Lateral Sclerosis Research
preprint

Intranasal delivery of MSC-derived small extracellular vesicles alleviates motor dysfunction and neuroinflammation in ALS mice and exhibits favorable systemic safety

Qing‐Ling Fu, 王树汉, Zhihui Wang, Dong-Xiao Lou, Changlin Lian, Yukai Wang, Yingchu Xie, Tian Tian, LongXin Huang, ZhiRou Zhou, Qi Sun, SiLin Yu, ChanGu Li, XiaoQing Liu
preprint en

Abstract

Abstract Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no curative therapy. Neuroinflammation, glial overactivation, neuromuscular junction (NMJ) damage and neuronal apoptosis are major pathological features of ALS. Mesenchymal stem cell-derived small extracellular vesicles (MSC-sEVs) are neuroprotective and anti-inflammatory and can cross the blood-brain barrier. Here, we investigated the therapeutic efficacy and systemic safety of intranasal MSC-sEVs in ALS mice. Methods sEVs were isolated from mesenchymal stem cells using anion exchange chromatography, and then lyophilized. The bioactivity of lyophilized MSC-sEVs was validated in a LPS-induced BV2 microglial inflammation model. The SOD1 G93A mice were administered by nasal administration, and motor function was assessed by grip strength and rotarod tests. Neuromuscular junction (NMJ) integrity in the gastrocnemius muscle was examined by immunofluorescence. Neuroinflammation and mitochondrial function-related proteins in the spinal cord and cerebral cortex were detected by western blot and immunofluorescence. Public transcriptomic datasets were used to explore the correlation between SYF2 and ALS-related molecular signatures and its regulatory role in mitochondrial gene expression. For safety evaluation, male and female C57BL/6 mice were also treated via intranasal administration, body weight, serum liver and kidney biochemical parameters, and liver and kidney histology were assessed. Results MSC-sEVs significantly ameliorated motor dysfunction in ALS mice, protected NMJ integrity, inhibited microglial and astrocyte overactivation, and reduced neuroinflammation. SYF2 was upregulated in ALS patients and correlated with DNA damage-related pathways, while SYF2 silencing upregulated multiple mitochondrial genes enriched in oxidative phosphorylation, suggesting that SYF2 may modulate mitochondrial gene expression in ALS. Safety verification showed that MSC-sEVs caused no adverse effects on mouse growth or liver and kidney function and even improved liver biochemical parameters, showing favorable biosafety. Conclusions Intranasal MSC-sEVs effectively alleviate neuroinflammation, preserve NMJ integrity and rescue motor impairment in ALS mice, with reliable systemic safety. The preserved bioactivity of lyophilized MSC-sEVs and the involvement of SYF2-mediated mitochondrial regulation support MSC-sEVs as a safe and promising translatable therapeutic candidate for ALS.

Research Square
First People's Hospital of Foshan (CN), The First Affiliated Hospital, Sun Yat-sen University (CN), Guangdong Provincial People's Hospital (CN)
National Natural Science Foundation of China
Good health and well-being
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon